Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Max Heiduk"'
Autor:
David Digomann, Max Heiduk, Charlotte Reiche, Jessica Glück, Christoph Kahlert, Peter Mirtschink, Anna Klimova, Florian Bösch, Torsten Tonn, Jochen Gaedcke, Michael Ghadimi, Jürgen Weitz, Lena Seifert, Adrian M. Seifert
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-9 (2023)
Abstract Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for treatment, and response predict
Externí odkaz:
https://doaj.org/article/c19f5bd9248f4e8393bbb8bdfd097f13
Autor:
Max Heiduk, Ioana Plesca, Jessica Glück, Luise Müller, David Digomann, Charlotte Reiche, Janusz von Renesse, Rahel Decker, Christoph Kahlert, Ulrich Sommer, Daniela E. Aust, Marc Schmitz, Jürgen Weitz, Lena Seifert, Adrian M. Seifert
Publikováno v:
JCI Insight, Vol 7, Iss 22 (2022)
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally a
Externí odkaz:
https://doaj.org/article/9a5a29027fcc4aadb45aea3cef95ab9a
Autor:
David Digomann, Johannes Strack, Max Heiduk, Ioana Plesca, Luise Rupp, Charlotte Reiche, Simone Nicolaus, Carolin Beer, Ulrich Sommer, Marc Schmitz, Marius Distler, Jürgen Weitz, Adrian M. Seifert, Lena Seifert
Publikováno v:
Cancers, Vol 15, Iss 8, p 2326 (2023)
Immunotherapy has shown promising results in multiple solid tumors and hematological malignancies. However, pancreatic ductal adenocarcinoma (PDAC) has been largely refractory to current clinical immunotherapies. The V-domain Ig suppressor of T-cell
Externí odkaz:
https://doaj.org/article/aac80fc54b8344ff92e69cea248a9c6a
Autor:
Ioana Plesca, Iva Benešová, Carolin Beer, Ulrich Sommer, Luise Müller, Rebekka Wehner, Max Heiduk, Daniela Aust, Gustavo Baretton, Michael P Bachmann, Anja Feldmann, Jürgen Weitz, Lena Seifert, Adrian M Seifert, Marc Schmitz
Publikováno v:
Cancers, Vol 14, Iss 5, p 1216 (2022)
Dendritic cells (DCs) play a key role in the orchestration of antitumor immunity. Activated DCs efficiently enhance antitumor effects mediated by natural killer cells and T lymphocytes. Conversely, tolerogenic DCs essentially contribute to an immunos
Externí odkaz:
https://doaj.org/article/e5a4820d9bd747be86ac1dd95b79bdde
Autor:
Lena Seifert, Ioana Plesca, Luise Müller, Ulrich Sommer, Max Heiduk, Janusz von Renesse, David Digomann, Jessica Glück, Anna Klimova, Jürgen Weitz, Marc Schmitz, Adrian M. Seifert
Publikováno v:
Cancers, Vol 13, Iss 6, p 1297 (2021)
T cells are the predominant immune cell population in the pancreatic tumor microenvironment. High CD8+ and Th1-polarized CD4+ T cell infiltration is associated with prolonged survival in human pancreatic ductal adenocarcinoma (PDAC). However, the exp
Externí odkaz:
https://doaj.org/article/e12300c9f3724f15985ef3cac669b06d
Autor:
Adrian M. Seifert, Annabel Eymer, Max Heiduk, Rebekka Wehner, Antje Tunger, Janusz von Renesse, Rahel Decker, Daniela E. Aust, Thilo Welsch, Christoph Reissfelder, Jürgen Weitz, Marc Schmitz, Lena Seifert
Publikováno v:
Cancers, Vol 12, Iss 10, p 2756 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a mostly immunosuppressive microenvironment. Tumor-draining lymph nodes (TDLN) are a major site for priming of tumor-reactive T cells and also tumor metastasis. However, the phenotype and fu
Externí odkaz:
https://doaj.org/article/c1c2f9608f604ec88e67535bc4046256
Autor:
Max Heiduk, Anna Klimova, Charlotte Reiche, David Digomann, Carolin Beer, Daniela E. Aust, Marius Distler, Jürgen Weitz, Adrian M. Seifert, Lena Seifert
Publikováno v:
Clinical Cancer Research.
Purpose: Immunotherapy has led to a fundamental shift in the treatment of several cancers. However, its efficacy in pancreatic ductal adenocarcinoma (PDAC) is limited. Understanding the expression of inhibitory immune checkpoint receptors (ICR) by in
Autor:
Barbara Seliger, Chiara Massa, Claudia Wickenhauser, Bernhard Hiebl, Christian V. Recktenwald, Max Heiduk, André Steven
Supplementary Methods, Figure Legends and Tables Supplementary Table I: Inhibitors used in this study Supplementary Table II: Summary of primers used for murine (m) and human (h) samples Supplementary Table III: Primer for murine promoter constructs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::686131edc61fdc97f2412a56eea88742
https://doi.org/10.1158/1541-7786.22514521
https://doi.org/10.1158/1541-7786.22514521
Autor:
Barbara Seliger, Chiara Massa, Claudia Wickenhauser, Bernhard Hiebl, Christian V. Recktenwald, Max Heiduk, André Steven
Supplementary Figure 3: Altered phenotype and growth properties of RAS transformants by CREB silencing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0da46c5bc945eb2268d6e7d9c59cdf2f
https://doi.org/10.1158/1541-7786.22514536.v1
https://doi.org/10.1158/1541-7786.22514536.v1
Autor:
Barbara Seliger, Chiara Massa, Claudia Wickenhauser, Bernhard Hiebl, Christian V. Recktenwald, Max Heiduk, André Steven
Supplementary Figure 6: Histology, immunohistochemistry and morphology of murine tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f367512fbb0201d0dd3a58231e472f2
https://doi.org/10.1158/1541-7786.22514524
https://doi.org/10.1158/1541-7786.22514524